{"title":"复方雪莲通胶囊对减少心血管疾病及相关眼科并发症的疗效：一项多中心回顾性研究","authors":"","doi":"10.1016/j.hermed.2024.100943","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>This study aims to explore the effectiveness and value of compound xueshuantong capsule (CXC) in the treatment of diseases by evaluating its potential to reduce cardiovascular diseases (CVDs) and ophthalmic complications.</div></div><div><h3>Methods</h3><div>A total of 5<!--> <!-->104 patients with fundus vascular diseases including retinal artery occlusion (RAO), retinal vein occlusion (RVO), diabetic retinopathy (DR), hypertensive retinopathy, periphlebitis of retina, age-related macular degeneration (AMD), central serous chorioretinopathy (CSC), and anterior ischaemic optic neuropathy (AION) were enroled across seven hospitals from 2002 to 2022. All participants were randomised categorised into two groups: CXC combination group (CXC alone or combined with hypoglycemic, lipid-lowering, or anti-hypertensive drugs, and other microcirculation and fundus angiopathy medications), and non-CXC group (only taking the above-mentioned medicines).</div></div><div><h3>Results</h3><div>Kaplan-Meier curves illustrated a lower incidence of cardio-cerebrovascular events and ophthalmic complications in CXC group compared with other group at a significant difference observed. Further stratification revealed a decreased risk of ophthalmic complications in CXC group, and supported by multivariate analysis through adjusting for baseline confounding factors.</div></div><div><h3>Discussion/Conclusions</h3><div>Our findings further confirmed the potential value of CXC in treating cardio-cerebrovascular diseases and associated ophthalmic complications, and accompanying with less side effects at the same time.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of compound xueshuantong capsule in reducing cardiovascular diseases and associated ophthalmic complications: a multi-centre retrospective study\",\"authors\":\"\",\"doi\":\"10.1016/j.hermed.2024.100943\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>This study aims to explore the effectiveness and value of compound xueshuantong capsule (CXC) in the treatment of diseases by evaluating its potential to reduce cardiovascular diseases (CVDs) and ophthalmic complications.</div></div><div><h3>Methods</h3><div>A total of 5<!--> <!-->104 patients with fundus vascular diseases including retinal artery occlusion (RAO), retinal vein occlusion (RVO), diabetic retinopathy (DR), hypertensive retinopathy, periphlebitis of retina, age-related macular degeneration (AMD), central serous chorioretinopathy (CSC), and anterior ischaemic optic neuropathy (AION) were enroled across seven hospitals from 2002 to 2022. All participants were randomised categorised into two groups: CXC combination group (CXC alone or combined with hypoglycemic, lipid-lowering, or anti-hypertensive drugs, and other microcirculation and fundus angiopathy medications), and non-CXC group (only taking the above-mentioned medicines).</div></div><div><h3>Results</h3><div>Kaplan-Meier curves illustrated a lower incidence of cardio-cerebrovascular events and ophthalmic complications in CXC group compared with other group at a significant difference observed. Further stratification revealed a decreased risk of ophthalmic complications in CXC group, and supported by multivariate analysis through adjusting for baseline confounding factors.</div></div><div><h3>Discussion/Conclusions</h3><div>Our findings further confirmed the potential value of CXC in treating cardio-cerebrovascular diseases and associated ophthalmic complications, and accompanying with less side effects at the same time.</div></div>\",\"PeriodicalId\":56077,\"journal\":{\"name\":\"Journal of Herbal Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Herbal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2210803324001003\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Herbal Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210803324001003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
Efficacy of compound xueshuantong capsule in reducing cardiovascular diseases and associated ophthalmic complications: a multi-centre retrospective study
Introduction
This study aims to explore the effectiveness and value of compound xueshuantong capsule (CXC) in the treatment of diseases by evaluating its potential to reduce cardiovascular diseases (CVDs) and ophthalmic complications.
Methods
A total of 5 104 patients with fundus vascular diseases including retinal artery occlusion (RAO), retinal vein occlusion (RVO), diabetic retinopathy (DR), hypertensive retinopathy, periphlebitis of retina, age-related macular degeneration (AMD), central serous chorioretinopathy (CSC), and anterior ischaemic optic neuropathy (AION) were enroled across seven hospitals from 2002 to 2022. All participants were randomised categorised into two groups: CXC combination group (CXC alone or combined with hypoglycemic, lipid-lowering, or anti-hypertensive drugs, and other microcirculation and fundus angiopathy medications), and non-CXC group (only taking the above-mentioned medicines).
Results
Kaplan-Meier curves illustrated a lower incidence of cardio-cerebrovascular events and ophthalmic complications in CXC group compared with other group at a significant difference observed. Further stratification revealed a decreased risk of ophthalmic complications in CXC group, and supported by multivariate analysis through adjusting for baseline confounding factors.
Discussion/Conclusions
Our findings further confirmed the potential value of CXC in treating cardio-cerebrovascular diseases and associated ophthalmic complications, and accompanying with less side effects at the same time.
期刊介绍：
The Journal of Herbal Medicine, the official journal of the National Institute of Medical Herbalists, is a peer reviewed journal which aims to serve its readers as an authoritative resource on the profession and practice of herbal medicine. The content areas of the journal reflect the interests of Medical Herbalists and other health professionals interested in the clinical and professional application of botanical medicines. The objective is to strengthen the research and educational base of herbal medicine with research papers in the form of case studies, original research articles and reviews, monographs, clinical trials and relevant in vitro studies. It also publishes policy statements, opinion pieces, book reviews, conference proceedings and profession related information such as pharmacovigilance reports providing an information source for not only the Herbal Practitioner but any Health professional with an interest in phytotherapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
